Skip to main content

Table 1 Dose levels of lapatinib and foretinib

From: A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Dose level

Foretinib/lapatinib dose

Number of cycles

Number of patients

1

30 mg/750 mg

2

2

20

1

2

30 mg/1000 mg

2

2

5

1

3

45 mg/1000 mg

2

2

3–4

4

4

45 mg/1250 mg

1–2

4

4

1

6

2

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us